For the quarter ended January 2026, Agilent Technologies (A) reported revenue of $1.8 billion, up 7% over the same period last year. EPS came in at $1.36, compared to $1.31 in the year-ago quarter.
The reported revenue represents a surprise of -0.27% over the Zacks Consensus Estimate of $1.8 billion. With the consensus EPS estimate being $1.37, the EPS surprise was -0.52%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Americas: $678 million versus the three-analyst average estimate of $704.33 million. The reported number represents a year-over-year change of +1.4%.
- Net Revenue- Asia Pacific: $602 million versus $604.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.7% change.
- Net Revenue- Europe: $518 million versus $486.16 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.9% change.
- Net Revenue- Life Sciences and Diagnostics Markets Segment: $679 million versus the six-analyst average estimate of $699.9 million.
- Net Revenue- Applied Markets: $361 million versus $354.15 million estimated by six analysts on average.
- Net Revenue- Agilent Crosslab Group: $758 million compared to the $748.58 million average estimate based on six analysts.
- Revenue by End Markets- Chemical and advanced materials: $422 million versus the three-analyst average estimate of $413.46 million. The reported number represents a year-over-year change of +11.4%.
- Revenue by End Markets- Environmental and Forensics: $177 million versus the three-analyst average estimate of $173.75 million. The reported number represents a year-over-year change of +2.9%.
- Revenue by End Markets- Diagnostics and Clinical: $263 million versus $254.2 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.
- Revenue by End Markets- Academia and Government: $130 million versus $144.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change.
- Revenue by End Markets- Pharmaceutical: $640 million versus the three-analyst average estimate of $633.34 million. The reported number represents a year-over-year change of +9.4%.
- Revenue by End Markets- Food: $166 million versus $166.52 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.2% change.
View all Key Company Metrics for Agilent here>>>
Shares of Agilent have returned -8.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilent Technologies, Inc. (A): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
